Structure-activity relationships of benzbromarone metabolites and derivatives as EYA inhibitory anti-angiogenic agents

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Pandey, Ram Naresh ^a   Wang, Tim Sen ^a,c   Tadjuidje, Emmanuel ^a,d   McDonald, Matthew G ^b   Rettie, Allan E ^b   Hegde, Rashmi S ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MIAMI UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1 BENZOFURAN 3 YL)(4 HYDOXYPHENYL)METHANONE; ANGIOGENESIS INHIBITOR; BENZBROMARONE; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANGIOGENIC SPROUTING; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL ASSAY; CELL MIGRATION; CELL PROLIFERATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME BINDING; ENZYME INHIBITION; HUMAN; HUMAN CELL; METABOLITE; MORPHOGENESIS; MOUSE; NONHUMAN; PROTEIN BINDING; RAT; STRUCTURE ACTIVITY RELATION; TUBULOGENESIS;

ANALYSIS OF VARIANCE; ANGIOGENESIS INHIBITORS; ANIMALS; BENZBROMARONE; CELL MOVEMENT; DNA-BINDING PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, INBRED C57BL; MICROTUBULES; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PHYSIOLOGIC; PROTEIN TYROSINE PHOSPHATASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84893169431     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084582     Document Type: Article

References (34)

1. Rayapureddi JP, Kattamuri C, Steinmetz BD, Frankfort BJ, Ostrin EJ et al. (2003) Eyes absent represents a class of protein tyrosine phosphatases. Nature 426: 295-298. doi:10.1038/nature02093. PubMed: 14628052. (Pubitemid 37463148)
2. Tootle TL, Silver SJ, Davies EL, Newman V, Latek RR et al. (2003) The transcription factor Eyes absent is a protein tyrosine phosphatase. Nature 426: 299-302. doi:10.1038/nature02097. PubMed: 14628053. (Pubitemid 37463149)
3. Li X, Oghi KA, Zhang J, Krones A, Bush KT et al. (2003) Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426: 247-254. doi:10.1038/nature02083. PubMed: 14628042. (Pubitemid 37463137)
4. Okabe Y, Sano T, Nagata S (2009) Regulation of the innate immune response by threonine-phosphatase of Eyes absent. Nature 460: 520-524. PubMed: 19561593.
5. Ohto H, Kamada S, Tago K, Tominaga SI, Ozaki H et al. (1999) Cooperation of six and eya in activation of their target genes through nuclear translocation of Eya. Mol Cell Biol 19: 6815-6824. PubMed: 10490620. (Pubitemid 29441865)
6. Tadjuidje E, Hegde RS (2013) The Eyes Absent proteins in development and disease. Cell Mol Life Sci 70: 1897-1913. doi:10.1007/s00018-012-1144-9. PubMed: 22971774.
7. Miller SJ, Lan ZD, Hardiman A, Wu J, Kordich JJ et al. (2010) Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis. Oncogene 29: 368-379. doi:10.1038/onc.2009.360. PubMed: 19901965.
8. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL (2012) Eya2 is required to mediate the pro-metastatic functions of Six1 via the induction of TGF-beta signaling, epithelial-mesenchymal transition, and cancer stem cell properties. Oncogene 31: 552-562. PubMed: 21706047.
9. Zhang L, Yang N, Huang J, Buckanovich RJ, Liang S et al. (2005) Transcriptional coactivator Drosophila eyes absent homologue 2 is upregulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 65: 925-932. PubMed: 15705892. (Pubitemid 40216453)
10. Robin TP, Smith A, McKinsey E, Reaves L, Jedlicka P et al. (2012) EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance. Mol Cancer Res 10: 1098-1108. doi:10.1158/1541-7786.MCR-12-0086. PubMed: 22723308.
11. Cook PJ, Ju BG, Telese F, Wang X, Glass CK et al. (2009) Tyrosine dephosphorylation of H2AX modulates apoptosis and survival decisions. Nature 458: 591-596. doi:10.1038/nature07849. PubMed: 19234442.
12. Krishnan N, Jeong DG, Jung SK, Ryu SE, Xiao A et al. (2009) Dephosphorylation of the C-terminal tyrosyl residue of the DNA damage-related histone H2A.X is mediated by the protein phosphatase eyes absent. J Biol Chem 284: 16066-16070. doi:10.1074/jbc.C900032200. PubMed: 19351884.
13. Tadjuidje E, Wang TS, Pandey RN, Sumanas S, Lang RA et al. (2012) The EYA Tyrosine Phosphatase Activity Is Pro-Angiogenic and Is Inhibited by Benzbromarone. PLOS ONE 7: e34806. doi:10.1371/journal.pone.0034806. PubMed: 22545090.
14. Rayapureddi JP, Kattamuri C, Chan FH, Hegde RS (2005) Characterization of a plant, tyrosine-specific phosphatase of the aspartyl class. Biochemistry 44: 751-758. doi:10.1021/bi0481794. PubMed: 15641802. (Pubitemid 40105506)
15. Jansen TL, Reinders MK, van Roon EN, Brouwers JR (2004) Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"? Clin Exp Rheumatol 22: 651. PubMed: 15485024.
16. Lee MH, Graham GG, Williams KM, Day RO (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Safety: An International Journal of Medical Toxicology and Drug Experience 31: 643-665. doi:10.2165/00002018-200831080- 00002. (Pubitemid 352019563)
17. McDonald MG, Rettie AE (2007) Sequential metabolism and bioactivation of the hepatotoxin benzbromarone: formation of glutathione adducts from a catechol intermediate. Chem Res Toxicol 20: 1833-1842. doi:10.1021/tx7001228. PubMed: 18020424.
18. Walter-Sack I, de Vries JX, Ittensohn A, Weber E (1990) Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles. Eur J Clin Pharmacol 39: 577-581. doi:10.1007/BF00316099. PubMed: 2095343.
19. Takahashi H, Sato T, Shimoyama Y, Shioda N, Shimizu T et al. (1999) Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone. Clin Pharmacol Ther 66: 569-581. doi:10.1053/cp.1999.v66.103378001. PubMed: 10613612. (Pubitemid 30014082)
20. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675. doi:10.1038/nmeth.2089. PubMed: 22930834.
21. Meijering E, Jacob M, Sarria JC, Steiner P, Hirling H et al. (2004) Design and validation of a tool for neurite tracing and analysis in fluorescence microscopy images. Cytometry A 58: 167-176. PubMed: 15057970. (Pubitemid 38509178)
22. Aplin AC, Fogel E, Zorzi P, Nicosia RF (2008) The aortic ring model of angiogenesis. Methods Enzymol 443: 119-136. PubMed: 18772014.
23. Reed MJ, Karres N, Eyman D, Vernon RB (2007) Culture of murine aortic explants in 3-dimensional extracellular matrix: a novel, miniaturized assay of angiogenesis in vitro. Microvasc Res 73: 248-252. doi:10.1016/j.mvr.2007.02.002. PubMed: 17363012. (Pubitemid 46601524)
24. de Vries JX, Walter-Sack I, Ittensohn A, Weber E, Empl H et al. (1993) Benzbromarone hydroxylation in man: defective formation of the 6-hydroxybenzbromarone metabolite. Clin Investig 71: 947-952. PubMed: 8312690. (Pubitemid 23327484)
25. Locuson CW 2nd, Wahlstrom JL, Rock DA, Jones JP (2003) A new class of CYP2C9 inhibitors: probing 2C9 specificity with high-affinity benzbromarone derivatives. Drug Metab Dispos 31: 967-971. doi:10.1124/dmd.31.7.967. PubMed: 12814975. (Pubitemid 36759068)
26. Donovan D, Brown NJ, Bishop ET, Lewis CE (2001) Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 4: 113-121. doi:10.1023/A:1012218401036. PubMed: 11806243. (Pubitemid 34032697)
27. Pandey RN, Rani R, Yeo EJ, Spencer M, Hu S et al. (2010) The Eyes Absent phosphatase-transactivator proteins promote proliferation, transformation, migration, and invasion of tumor cells. Oncogene 29: 3715-3722. doi:10.1038/onc.2010.122. PubMed: 20418914.
28. Wu K, Li Z, Cai S, Tian L, Chen K et al. (2013) EYA1 Phosphatase Function Is Essential to Drive Breast Cancer Cell Proliferation through Cyclin D1. Cancer Res 73: 4488-4499. doi:10.1158/0008-5472.CAN-12-4078. PubMed: 23636126.
29. Uchida S, Shimada K, Misaka S, Imai H, Katoh Y et al. (2010) Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes. Drug Metab Pharmacokinet 25: 605-610. doi:10.2133/dmpk.DMPK-10- NT-040. PubMed: 20962433.
30. Wrobel J, Sredy J, Moxham C, Dietrich A, Li Z et al. (1999) PTP1B inhibition and antihyperglycemic activity in the ob/ob mouse model of novel 11-arylbenzo[b]naphtho[2,3-d]furans and 11-arylbenzo[b]naphtho[2,3-d]thiophenes. J Med Chem 42: 3199-3202. doi:10.1021/jm990260v. PubMed: 10464006. (Pubitemid 29409708)
31. Wiesmann C, Barr KJ, Kung J, Zhu J, Erlanson DA et al. (2004) Allosteric inhibition of protein tyrosine phosphatase 1B. Nat Struct Mol Biol 11: 730-737. doi:10.1038/nsmb803. PubMed: 15258570. (Pubitemid 39014498)
32. Malamas MS, Sredy J, Moxham C, Katz A, Xu W et al. (2000) Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J Med Chem 43: 1293-1310. doi:10.1021/jm990560c. PubMed: 10753467. (Pubitemid 30212571)
33. McDonald MG, Au NT, Wittkowsky AK, Rettie AE (2012) Warfarin-amiodarone drug-drug interactions: determination of [I](u)/K(I,u) for amiodarone and its plasma metabolites. Clin Pharmacol Ther 91: 709-717. doi:10.1038/clpt.2011.283. PubMed: 22398967.
34. Trujillo TC, Nolan PE (2000) Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf 23: 509-532. doi:10.2165/00002018-200023060- 00003. PubMed: 11144659. (Pubitemid 32001513)